Evidence map›Paper›PMID 42013315›Full record

ArticleCancer discovery2026

scSurvival: Single-Cell Survival Analysis of Clinical Cancer Cohort Data at Cellular Resolution.

Tao Ren, Faming Zhao, Canping Chen, Le Zhou, Ling-Yun Wu, Gordon B Mills, Lisa M Coussens, Zheng Xia

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tao Ren *Biomedical Engineering Department, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-6486-7338
Faming Zhao *Biomedical Engineering Department, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-8238-3863
Canping ChenBiomedical Engineering Department, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-4021-8592
Le ZhouBiomedical Engineering Department, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0005-0043-7848
Ling-Yun WuAcademy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China.ORCID 0000-0001-9487-0215
Gordon B MillsKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0144-9614
Lisa M CoussensKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-2389-1865
Zheng XiaBiomedical Engineering Department, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-3364-8324

Funding

Systematic Characterization and Targeting of Neomorphic Drivers in CancerU01CA281902 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Benjamin Deneen, Han Liang · 2023 to 2026
$3.5M
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.U01CA253472 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORKUT, ANIL, LIANG, HAN · 2021 to 2025
$2.6M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
DOD Prostate Cancer Research Program (PCRP) HT94252410551National Cancer Institute (NCI) R01CA283171National Cancer Institute (NCI) U01CA253472National Cancer Institute (NCI) U01CA281902National Cancer Institute (NCI) U24CA264128National Institute of General Medical Sciences (NIGMS) R01GM147365National Institutes of Health (NIH) S10OD034224NCI NIH HHS U01 CA253472NCI NIH HHS U01 CA281902Silver Family Innovation FoundationThe National Foundation for Cancer ResearchThe Susan G. Komen Foundation
6 · The paper itself

Abstract

Survival analysis is fundamental to cancer research. Advances in technology have enabled an increasing number of cohort-level cancer studies to incorporate single-cell sequencing alongside clinical survival data. However, no effective strategy currently exists for directly modeling survival outcomes from single-cell data. To address this gap, we present scSurvival, an attention-based multiple-instance Cox regression framework that models each tumor sample as an ensemble of cells to predict survival outcomes at both the patient and single-cell levels. To handle high dimensionality, sparsity, and batch effects, scSurvival integrates a variational autoencoder-based feature extraction module with generative modeling to enhance feature robustness and cross-batch generalizability. Comprehensive simulations demonstrate scSurvival's superior performance and scalability. In melanoma and liver cancer single-cell RNA sequencing (scRNA-seq) cohorts, scSurvival accurately predicts patient outcomes and identifies the cell subpopulations most critical to survival. Overall, scSurvival enables robust prediction of patient survival while uncovering survival-associated cell subpopulations, advancing single-cell survival analysis in cancer research. SIGNIFICANCE: Survival analysis is central to clinical oncology, yet no effective tools currently model survival outcomes directly from single-cell data. scSurvival bridges this gap by predicting patient outcomes and identifying key subpopulations from scRNA-seq with survival information, enabling scalable analyses and promoting broader adoption of cohort-level single-cell profiling in cancer research.

Indexed as

NeoplasmsSingle-Cell AnalysisCohort StudiesHumansSingle-Cell Gene Expression AnalysisSurvival Analysis

Identifiers

PMID42013315
PMCPMC13133615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.